Envisioning a Healthier Tomorrow
We believe in a world where technology targets cancer at its earliest stage.
Through early diagnosis and precision medicine, we move closer each day to the ultimate goal:
a future free of preventable cancer deaths.
Through early diagnosis and precision medicine, we move closer each day to the ultimate goal:
a future free of preventable cancer deaths.
84%
Accuracy in machine learning models
3Billion
Data points processed daily by our systems
60+
Patents filed in various
AI technologies
42PB
Of data is stored in our systems
The Renovaro timeline
August 2023
Renovaro launches to develop cell,
gene, and immunotherapies
gene, and immunotherapies
Renovaro begins as a therapeutics company specializing in the genetic modification of dendritic cells to fight cancer and immune-mediated diseases.
September 2023
GEDiCube identifies 10K
cancer-specific biomarkers
cancer-specific biomarkers
GEDiCube, an Amsterdam-based technology startup uses proprietary algorithms to identify 10K plus biomarkers spanning 13 cancer types.
February 2024
Merger between Renovaro
and GEDiCube
and GEDiCube
GEDiCube is officially acquired by Renovaro in a stock-for-stock acquisition; GEDiCube is rebranded as Renovaro Cube, and LA-based Renovaro is rebranded as Renovaro Biosciences.
December 2024
Renovaro receives LUMINA grant
Renovaro receives grant approval for LUMINA project to develop advanced minimal residual disease detection platform for lung cancer from the Eurostars funding program.
February 2025
Renovaro receives 15M
in equity committed
in equity committed
Renovaro fundraising results in 15M in equity to advance its AI-driven cancer diagnostics and therapeutic development programs.
April 2025
Renovaro merges with BioSymetrics
Renovaro acquires New York based BioSymetrics, a translational medicine company.
